Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Cancer-associated cachexia (CC) is a progressive syndrome characterized by unintentional weight loss, muscle atrophy, fatigue, and poor outcomes that affects most patients with pancreatic ductal adenocarcinoma (PDAC). The ability to identify and classify CC stage along its continuum early in the disease process is challenging but critical for management. Objectives: The main objective of this study was to determine the prevalence of CC stage overall and by sex and race and ethnicity among treatment-naïve PDAC cases using clinical, nutritional, and functional criteria. Secondary objectives included identifying the prevalence and predictors of higher symptom burden, supportive care needs, and quality of life (QoL), and examining their influence on overall survival (OS). Materials and methods: A population-based multi-institutional prospective cohort study of patients with PDAC was conducted between 2018 and 2021 by the Florida Pancreas Collaborative. Leveraging patient-reported data and laboratory values, participants were classified at baseline into four stages [non-cachexia (NCa), pre-cachexia (PCa), cachexia (Ca), and refractory cachexia (RCa)]. Multivariate regression, Kaplan Meier analyses, and Cox regression were conducted to evaluate associations. Results: CC stage was estimated for 309 PDAC cases (156 females, 153 males). The overall prevalence of NCa, PCa, Ca, and RCa was 12.9%, 24.6%, 54.1%, and 8.4%, respectively. CC prevalence across all CC stages was highest for males and racial and ethnic minorities. Criteria differentiated NCa cases from other groups, but did not distinguish PCa from Ca. The most frequently reported symptoms included weight loss, fatigue, pain, anxiety, and depression, with pain significantly worsening over time. The greatest supportive care needs included emotional and physical domains. Males, Black people, and those with RCa had the worst OS. Conclusions: Using clinical, nutritional, and functional criteria, nearly one-quarter of the PDAC cases in our diverse, multi-institutional cohort had PCa and 62.5% had Ca or RCa at the time of diagnosis. The PCa estimate is higher than that reported in prior studies. We recommend these criteria be used to aid in CC classification, monitoring, and management of all incident PDAC cases. Findings also highlight the recommendation for continued emotional support, assistance in alleviating pain, and supportive care needs throughout the PDAC treatment journey.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma
- Date Crossref
- 23/07/2024
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Moffitt Cancer Center pays non établi dans la noticeÉtablissement de santé
-
University of Maryland pays non établi dans la noticeUniversité ou école supérieure
-
Baylor Scott & White Health pays non établi dans la noticeÉtablissement de santé
-
Baylor Scott & White Research Institute Research Analytics and Development Cores pays non établi dans la noticeOrganisation à but non lucratif
-
University of Miami pays non établi dans la noticeUniversité ou école supérieure
-
University of Utah pays non établi dans la noticeUniversité ou école supérieure
-
Palmetto General Hospital Center for Advanced Surgical Oncology pays non établi dans la noticeÉtablissement de santé
-
AdventHealth Orlando pays non établi dans la noticeÉtablissement de santé
-
Translational Research Institute for Metabolism and Diabetes pays non établi dans la noticeStructure de recherche
-
AdventHealth pays non établi dans la noticeOrganisation à but non lucratif
-
St. Anthony’s Hospital Department of Surgery pays non établi dans la noticeÉtablissement de santé
-
Florida State University pays non établi dans la noticeUniversité ou école supérieure
Moffitt Cancer Center, University of Maryland et Baylor Scott & White Health, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.